Shots:
- XtalPi has entered into a strategic collaboration with DoveTree Medicines to identify novel therapeutics across oncology, immunology, inflammation, neurology, & metabolic diseases, leveraging XtalPi’s de novo drug discovery platform
- As per the deal, DoveTree will gain exclusive global rights to develop & commercialize multiple therapeutics from the collaboration, in exchange for a $51M upfront, $49M in near-term payments, & ~$5.89B in development & commercial milestones as well as tiered royalties
- XtalPi’s de novo drug discovery platform combines quantum physics, AI-driven design, & robotic lab-in-the-loop to accelerate development of small molecules, biologics, ADCs, and molecular glues with greater accuracy & efficiency
Ref: PRNewswire | Image: DoveTree Medicines and XtalPi| Press Release
Related News:- Knight Therapeutics and Incyte Expand Latin America Agreement to Include Retifanlimab and Axatilimab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
